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Abstract 
Background Although congenital adrenal hyperplasia (CAH) is known to be associated 
with adrenal crises (AC), its association with patient- or clinician-reported sick day 
episodes (SDE) is less clear.
Methods Data on children with classic 21-hydroxylase deficiency CAH from 34 centers 
in 18 countries, of which 7 were Low or Middle Income Countries (LMIC) and 11 were 
High Income (HIC), were collected from the International CAH Registry and analyzed to 
examine the clinical factors associated with SDE and AC.
Results A total of 518 children—with a median of 11 children (range 1, 53) per center—
had 5388 visits evaluated over a total of 2300 patient-years. The median number of AC 
and SDE per patient-year per center was 0 (0, 3) and 0.4 (0.0, 13.3), respectively. Of the 
1544 SDE, an AC was reported in 62 (4%), with no fatalities. Infectious illness was the 
most frequent precipitating event, reported in 1105 (72%) and 29 (47%) of SDE and AC, 
respectively. On comparing cases from LMIC and HIC, the median SDE per patient-year 
was 0.75 (0, 13.3) vs 0.11 (0, 12.0) (P < 0.001), respectively, and the median AC per patient-
year was 0 (0, 2.2) vs 0 (0, 3.0) (P = 0.43), respectively.
Conclusions The real-world data that are collected within the I-CAH Registry show wide 
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these data become increasingly used as a clinical benchmark in CAH care, there is a need 
for further research to improve and standardize the definition of SDE.
Key Words:  21-hydroxylase deficiency, adrenal insufficiency, adrenal crisis, congenital adrenal hyperplasia, registry
Congenital adrenal hyperplasia (CAH) is an autosomal re-
cessive condition with an incidence of approximately 1 in 
15 000 and is most commonly due to 21-hydroxylase defi-
ciency (1). In this form of CAH, a variable abnormality in 
steroidogenesis can result in varying levels of glucocorticoid 
(GC) and mineralocorticoid deficiency and in its most severe 
form, classic CAH, the patient may have severe primary ad-
renal insufficiency (2). CAH is the commonest cause of pri-
mary adrenal insufficiency in childhood (3), with a lifelong 
requirement for GC replacement and in most patients also 
mineralocorticoid replacement. Although GC treatment has 
improved survival in those with adrenal insufficiency (4), the 
risk of acute adrenal insufficiency, also known as an adrenal 
crisis (AC) has not been eliminated, with life expectancy re-
maining less than that of the general population (5, 6). An AC 
is usually associated with hospitalization, but the incidence 
of AC is very variable, with rates of between 5.2 and 10.9 
per 100 person-years recently reported in children with CAH 
(7-10). It is possible that some of this variation is related to 
lack of a universally accepted definition of AC as well as its 
prodrome, often referred to as a sick day episode (SDE) (11, 
12); it is also possible that there may be other factors that 
influence this variation, some that are patient-dependent and 
some that reflect on health care delivery (13). Nevertheless, 
there is increasing consensus that the avoidance of acute ad-
verse events due to adrenal insufficiency is one of the most 
important outcomes that can be routinely measured (14, 15).
Given the rarity of CAH as well as AC in children, 
knowledge on the epidemiology of acute adrenal insuf-
ficiency–related adverse events, including SDE, in CAH 
is limited (7-10, 16, 17), with a paucity of data in large, 
multicenter, international cohorts. The International 
Congenital Adrenal Hyperplasia Registry (I-CAH) repre-
sents a valuable resource for evaluating outcomes in this 
rare condition (18). In this study, using data from the 
I-CAH Registry, we sought to investigate the occurrence 
of adverse events, including SDE and AC, in children with 
classic 21-hydroxylase deficiency CAH and examine the as-
sociation of these outcomes with clinical variables.
Methods
Study population
All patients under the age of 18 years who were registered 
as having 21-hydroxylase deficiency CAH were identified 
from the I-CAH Registry (https://home.i-cah.org/) in July 
2019. The I-CAH Registry is an international database of 
pseudonymized information on patients with CAH and is 
approved by the National Research Ethics Service in the 
United Kingdom as a research database of information that 
is collected as part of routine clinical care (18). The data 
within the registry are deposited by clinicians following 
informed consent from patients or guardians. Only those 
cases of 21-hydroxylase deficiency on GC with or without 
mineralocorticoid (fludrocortisone [FC]) were included. 
For the purpose of this study, the phenotypic classification 
into salt-wasting and simple virilizing CAH was based on 
concurrent treatment with FC.
Clinical data collection
The I-CAH Registry collects data on acute adrenal insuf-
ficiency–related adverse events since a patient’s last clinic 
visit. Clinicians with cases meeting the inclusion criteria 
were approached to enter data for a minimum of 2 clinic 
visits per patient per year. SDE and AC were based on the 
clinical judgment of the reporting clinician. For each SDE, 
data were available on: the duration of SDE (number of 
days); any predisposing condition at the time of SDE (in-
fectious illness, surgery, other, not known); management 
of each SDE, including sick day management of oral 
steroids (doubled, >doubled, not increased, not known) 
and the requirement for intramuscular hydrocortisone 
(HC) injection (yes, no, not known); the occurrence of 
AC (yes, no, not known); the need for health profes-
sional input (self-managed at home, health professional 
only, emergency room, admission to hospital, intensive 
care unit). Data were also gathered about GC and FC 
regimens (preparation, dose, frequency) at the time of 
clinic visits. HC-equivalent dose (ED) was calculated by 
multiplying prednisolone dose by 5 or dexamethasone 
dose by 80 (19, 20). Total GC dose (HC-equivalent) was 
converted from mg to mg per m2 using the Mosteller for-
mula for calculation of body surface area (BSA) (21), or 
using predefined BSA values for weight as outlined in the 
British National Formulary for Children (22). GC and 
FC doses were categorized as low, normal, or high, based 
on the Endocrine Society clinical practice guidance for 
21-hydroxylase deficiency CAH (2018) (1) as follows: 
GC low <10  mg/m2/day, normal 10 to 15  mg/m2/day, 
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Statistical analysis
A longitudinal analysis of repeated measures reported from 
multiple visits was performed. The main outcome measures 
were occurrence of SDE, an increase in sick day oral GC dose, 
HC injection, AC, and hospitalization defined as attendance 
at the emergency room or admission to hospital. Multilevel 
logistic regressions were applied to examine the association 
of these outcome measures with clinical data obtained at 
each visit including age, sex, phenotype, GC, and FC dose. 
Accordingly, a 2-level multilevel regression model was built 
with individual patients (level 1) nested within centers (level 
2). Random (intercept) effects for both levels were included 
in the modeling to allow variations between individuals and 
centers to be accounted for. The observed frequency of SDE 
and AC was determined as incidence rate, calculated as the 
number of SDE and AC divided by person-years. For assess-
ment of geographical differences in the occurrence of SDE 
and AC, participating countries were categorized as those 
from a low or middle income country (LMIC) or from a 
high income country (HIC) as defined by the 2019 World 
Bank classification (23). Inter-group comparison for these 
variables was performed by the Mann-Whitney U test. The 
Fisher Exact test was performed to compare proportions in 
different groups. Results are reported as frequencies and per-
centages, median (with ranges) or odds ratios (OR) and 95% 
confidence intervals (CI). Data analysis was performed using 
R statistical software version 3.5.3 and Minitab version 18 
statistical software (Minitab LLC, State College, PA, USA).
Results
Case selection
At the time of the study, 1426 cases of CAH were 
registered in the I-CAH Registry. Data on clinic visits 
including adverse events were available for 518 children 
younger than 18  years with 21-hydroxylase deficiency 
CAH (Fig. 1). There was no significant difference in the 
proportion of cases from HIC or LMIC countries, CAH 
type, or sex assigned between those with and without 
clinic visits data (24). Of the 518 children, 275 (53%) 
were girls, 459 (89%) had salt-wasting CAH and 59 
(11%) had simple virilizing CAH. These children were re-
ported from 34 centers in 18 countries with a median of 
11 cases per center (1, 53) and 316 (61%) were from a 
high-income country (HIC). A total of 5388 clinic visits, 
occurring between 1984 and 2019, were evaluated in the 
518 children, comprising a total of 2300 patient-years 
(Table 1). The median duration of follow-up per patient 
was 3 years (0.1, 17.9), with a median of 2.9 visits (0.3, 
25.7) per patient-year. The median patient age at the time 
of the visits was 2 years (0, 17.9).
Steroid replacement
Of the 5388 clinic visits, information on steroid replace-
ment was available in 5250 visits (97%). Of the 518 chil-
dren, 435 (84%) were receiving HC, with 19 (3.5%) and 
7 (1.5%) receiving prednisolone and dexamethasone, re-
spectively; 16 children (3%) were taking a combination of 
different types of GC. HC use was documented in 4733 
visits (90%) and the median steroid replacement dose, as 
HC ED, was 12.5 mg/m2/day (2.3, 71.4). In the 4226 visits 
where GC doses were known, the GC doses were reported 
to be within the recommended HC ED of 10 to 15 mg/m2/
day in 2019 visits (48%) (Table 1). Of the 518 children, 
459 (89%) were receiving FC at the time of clinic visits, 
with a median dose of 93.8 µg/day (12.5, 500) and doses 
were reported to be within the recommended range of 50 
to 200 µg/day in 4374 visits (90%) (Table 1).
Figure 1. Participant selection from the I-CAH Registry. Abbreviations: 21-OHD, 21-hydroxylase deficiency; CAH, congenital adrenal hyperplasia; 
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Occurrence of sick day episodes and 
adrenal crises
Of the 5388 visits in 518 children, a total of 1544 SDE were 
reported in 1089 visits (20%) from 334 children (64%), of 
whom 167 (50%) were female. Based on a total observation 
period of 2300 patient-years, the SDE incidence rate was cal-
culated at 67 per 100 patient-years and the median duration 
of a SDE was 3  days (1, 41). Of the 1089 visits where a 
SDE was reported, in 989 (91%), the reported number of 
SDE since last clinic visit was ≤2. A median of 1 SDE (1, 
8) was reported per patient per visit, and the median number 
of SDE per patient-year per center was 0.4 (0, 13.3) (Fig. 2). 
The median SDE per patient-year was 0.75 (0, 13.3) vs 0.11 
(0, 12.0); P < 0.001, in HIC and LMIC countries, respect-
ively. Of the 1544 SDE, 62 events (4%) were associated with 
an AC in 49 out of 334 children (15%), all of whom had 
salt-wasting CAH and of whom 22 (45%) were female. The 
overall median AC per patient-year was 0 (0, 3), with no sig-
nificant difference between HIC and LMIC countries, (0 [0, 
2.2] vs 0 [0, 3.0]; P = 0.43), respectively (Fig. 2). There was 
no AC-related mortality reported among these children. The 
AC incidence rate in those children who had an SDE was 
3.9 per 100 patient-years, with an overall AC incidence rate 
of 2.7 per 100 patient-years for all children. On examining 
temporal trends, from 1980 to 2000, 12 AC were reported in 
association with 37 SDEs in a total of 6 patients; thus, 32% 
of SDEs were associated with an AC. For the same 20-year 
period after 2000, 50 AC were reported in 1507 SDEs in a 
total of 43 patients; thus, only 3% of SDEs were associated 
with an AC following the year 2000.
Table 1. Characteristics of Children With 21-Hydroxylase Congenital Adrenal Hyperplasia, at Clinic Visits (n = 5388)


















All 518 5388 (total) 9 (1, 42) 2300 3.0 (0.1, 17.9) 1744 2.9 (0.3, 25.7)
Sex F 275 2821 (52.4) 9 (1, 35) 1277 3.0 (0.1, 17.9) 881 2.9 (0.3, 18.2)
 M 243 2567 (47.6) 9 (1, 42) 1003 3.0 (0.2, 17.9) 863 3.0 (0.4, 25.7)
CAH pheno-
type
SW 459 5086 (94.4) 9 (1, 42) 1984 3.0 (0.1, 17.9) 1549 3.0 (0.3, 25.7)
 SV 59 302 (5.6) 9 (1, 35) 296 3.0 (0.2, 17.9) 195 2.5 (0.5, 14.7)
Age at visit, y <1 418 1621 (30.1) 3 (1, 16) 234 0.7 (0.0,1.0) 2770 5.9 (2.3, 51.4)
 1–4.9 422 2427 (45.0) 5 (1, 18) 893 2.0 (0.2, 4.6) 1255 2.6 (0.6, 25.7)
 5–14.9 189 1147 (21.3) 5 (1, 26) 606 2.2 (0.0, 9.7) 578 2.7 (0.9, 22.5)
 15–17.9 61 193 (3.6) 3 (1, 12) 85 1.5 (0.2, 2.6) 170 2.3 (1.3, 10.4)
Number of 
SDE
0 512 4299 (79.8) 7 (1, 42) 2142 2.9 (0.0, 17.9) 1665 2.6 (0.3, 51.4)
 1 311 816 (15.1) 2 (1, 12) 667 0.9 (0.1, 17.6) 858 2.9 (0.2, 27.7)
 2–3 129 231 (4.3) 1 (1, 6) 165 0.3 (0.1, 14.0) 376 3.0 (0.1, 22.5)
 ≥4 33 42 (0.8) 1 (1, 5) 17 0.3 (0.3, 2.7) 96 3.0 (0.8, 4.5)
Daily GC 
dosea
Normal 423 2019 (47.8) 4 (1, 24) 1224 1.8 (0.0, 17.2) 1508 2.7 (0.2, 53.3)
(HC ED mg/
m2/d)
High 341 1201 (28.4) 3 (1, 17) 763 0.7 (0.0, 17.8) 1762 3.0 (0.2, 65.5)
 Low 287 1006 (23.8) 3 (1, 16) 496 0.9 (0.1, 17.2) 999 3.0 (0.3, 34.3)
 Not known 282 1162 3 (1, 20) 700 1.2 (0.0, 17.6) 861 3.0 (0.1, 30.0)
Daily FC 
dosea
Normal 466 4374 (90.2) 8 (1, 40) 1925 3.0 (0.1, 17.8) 1629 2.9 (0.2, 45.0)
(µg/d) High 36 111 (2.3) 2 (1, 10) 23 0.3 (0.0, 2.7) 372 5.4 (1.2, 55.4)
 Low 95 359 (7.4) 2 (1, 16) 160 0.9 (0.2, 6.4) 283 3.0 (0.3, 8.7)
 Not known 143 544 2 (1, 25) 296 0.3 (0.0, 17.6) 695 3.0 (0.3, 65.5)
GC and FC doses were categorized as low, normal, or high, based on Endocrine Society clinical practice guidance for 21-hydroxylase deficiency CAH (2018) (1) as 
follows: GC low <10 mg/m2/day, normal 10 to 15 mg/m2/day, high >15 mg/m2/day; FC low <50 µg/day, normal 50-200 µg/day, high >200 µg/day. 
Abbreviations: CAH, congenital adrenal hyperplasia; FC, fludrocortisone (mcg/day); GC, glucocorticoid; HC ED, hydrocortisone equivalent dose (mg/m2/day); 
SDE, sick day episodes.
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Risk factors for sick day episodes and 
adrenal crises
Infectious illness was the most frequent event associated 
with SDE and AC across all ages, reported in 1105 of 
1544 SDE (72%) and in 29 of 62 AC episodes (47%). 
Surgery was reported as a factor predisposing to SDE in 
58 (4%) episodes and no predisposing factor was speci-
fied in 381 SDE (24%) and 33 AC (53%). Younger chil-
dren (aged 1-4 years) and adolescents (15-18 years) had a 
greater likelihood of a SDE (OR 2.05 [95% CI, 1.63-2.59] 
and OR 1.68 [95% CI, 1.37-2.06]; both P < 0.001, re-
spectively) and an increase in sick day oral GC (OR 2.11 
[95% CI, 1.63-2.73]; P < 0.001 and OR 1.98 [95% CI, 
1.57-2.49]; P < 0.01, respectively) compared with chil-
dren <1 year of age (Fig. 3). Compared to girls, boys were 
more likely to have SDE (OR 1.41 [95% CI, 1.14-1.75]; 
P < 0.01) and an increase in sick day oral GC (OR 1.37 
[95% CI, 1.08-1.74]; P < 0.01). Children receiving lower 
GC doses (HC ED < 10 mg/m2/day) were more likely to 
have a SDE (OR 2.00 [95% CI, 1.53-2.63]; P < 0.001) 
and an increase in sick day oral GC (OR 2.27 [95% CI, 
1.68-3.08]; P < 0.001) than those on higher GC doses 
(HC ED > 15  mg/m2/day). Similarly, children receiving 
GC doses within the recommended range (HC ED of 
10-15mg/m2/day) were more likely to have SDE (OR 1.47 
[95% CI, 1.17-1.85]; P < 0.01) and an increase in sick day 
oral GC (OR 1.73 [95% CI, 1.33-2.24]; P < 0.001), than 
children on higher GC doses (HC ED > 15  mg/m2/day). 
Due to the small number of AC events overall, which de-
crease further when broken down over risk factor levels, 
the multilevel regression model parameters could not be 
reliably estimated and are not reported.
Management of adverse events
Of the 1544 reports of SDE, there was information on a 
change in the patient’s usual management documented in 
1451 SDE (94%). More specifically, an increase in oral GC 
dose was noted in 1147 episodes (85%), HC injection was 
administered in 176 SDE (13%), and information on med-
ical input was available in 1419 SDE (92%) (Fig. 4). A total 
of 858 SDE (60%) were self-managed in the community 
and of these, 6 (1%) were associated with an AC. In 561 
SDE (40%), medical input, including hospitalization was 
sought and 55 (10%) of these were associated with an AC. 
In total, of the 62 episodes of AC that were reported, 55 
(90%) were associated with hospitalization. An increase 
in oral GC or HC injection administration was reported 
in 52 (84%) episodes of AC; in the remaining 10 (16%) 
episodes of AC, there was no information regarding an in-
crease in oral GC dose or the administration of HC injec-
tion; however, all 10 of these episodes were associated with 
hospitalization.
Discussion
We report the largest multicenter, international cohort 
study to date evaluating the epidemiology of acute ad-
renal insufficiency–related adverse events in children with 
21-hydroxylase deficiency CAH. While the majority of 
studies have measured AC, this is the first study to obtain a 
more complete perspective on adverse events by measuring 
SDE, episodes associated with sick day GC doses, and hos-
pitalization in a global cohort of children.
Interestingly, the incidence rate of AC of 2.7 to 3.9 per 
100 patient-years is at the lower end of the range that has 
Figure 2. A. Sick day episodes (SDE) per patient-year per country. Countries labeled “A” to “R.” B. Adrenal crisis (AC) episodes per patient per country. 
Countries labeled “A” to “R.” Each point represents the median number of SDE or AC per patient-year for each patient in that country. The white 
diamond symbol indicates the median number of SDE or AC per patient-year for all patients in that specific country. The dashed horizontal black 
lines indicate the overall median (and 75th centile values for SDE) for SDE and AC per patient-year for all countries. Abbreviations: HIC, high income 
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Figure 3. Association of age, sex phenotype, and medication dose with sick day episodes (A), an increase in sick day oral GC (B) and hospitalization 
(C). Abbreviations: FC, fludrocortisone (µg/day); GC, glucocorticoid (hydrocortisone-equivalent dose, mg/m2/day); SW, salt-wasting CAH; SV, simple 
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been reported previously (7-10, 25). This is perhaps a re-
flection of improvements in parent/patient education and 
increased awareness of AC among families and clinicians. It 
is also useful to note that overall, less than 5% of SDE were 
associated with an AC. While it is possible that the manage-
ment of SDE prevented an AC in these cases, confirmation 
of a causal link will require further study. Notably, all AC 
events occurred in children with the salt-wasting pheno-
type and there were no fatalities. In addition, a lower per-
centage of SDEs were associated with AC in the 2 decades 
after 2000 compared to previously; however, these tem-
poral trends may not be reliable, as the data from the older 
cohort is more likely to suffer from recall bias. Therefore, 
there is a need to look at temporal trends in more detail and 
this will become easier to study as regular data reporting 
is sustained over the longer-term by participating centers. 
The SDE incidence rate of 68 per 100 patient-years also de-
serves attention and further exploration. While controversy 
remains about the definition of a SDE as well as its appro-
priate management (16, 26, 27), a change in the patient’s 
usual medical management, including an increase in oral 
GC, HC administration, hospitalization, or documentation 
of a predisposing factor was noted in 94% of SDE. SDE 
incident rates have not been reported previously; thus, it 
is unclear as to whether the currently reported SDE rate is 
particularly high or low. Patients and parents, themselves, 
may have a different definition of a SDE compared with 
their clinician and this could be explored in the future by 
comparing patient/parent reporting to clinician reporting, 
with the inclusion of more objective criteria for SDE (28).
Infectious illnesses were the commonest event associ-
ated with SDE and AC, reported in more than two-thirds 
of all SDE and almost half of all cases of AC, as reported 
in previous literature (7-9, 16, 29). The precipitating event 
in AC was unknown in half of all cases; it is likely that fu-
ture studies incorporating prospective data collection may 
facilitate differentiation between specific etiology of infec-
tious illness in children having SDE and AC. More recently, 
it has been speculated that patients with primary adrenal 
insufficiency, including CAH, may have a greater predis-
position to infections (30) and these associations require 
further investigation.
Our data show wide variation in the median number of 
SDEs occurring per patient-year among centers. Moreover, 
more than half of patients with SDEs were self-managed 
at home but the majority of those who had an AC were 
hospitalized. A number of those who were hospitalized did 
not have an AC reported, thus raising the issue about the 
Figure 4. The management of sick day episodes (n = 1544). (A) Stress dosing, (B) HC injection, (C) AC occurrence, (D) Emergency attendance. 
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overlapping definitions of SDE and ACs. In the absence of 
a clearer distinction between an AC and a SDE, it is pos-
sible that hospitalization may be a better definition of a 
significant adverse event related to adrenal insufficiency. 
However, it is of course possible that different centers 
may have a different threshold for “hospitalizing” a pa-
tient with an adrenal insufficiency–related adverse event. 
This threshold for hospitalization may depend on several 
factors including health care delivery models, health care 
utilization costs, patient education, as well as the perceived 
competence of the patient in self-managing their condition 
(9, 31, 32). In addition, patients from HIC countries had a 
higher median SDE per patient-year compared with those 
from LMIC countries. One may expect that patients from 
LMIC and more deprived communities would have greater 
SDEs and ACs, due to issues such as reduced access to hos-
pital care and medication. Thus, the factors that influence 
these results require further evaluation.
The optimal management of children with CAH re-
quires GC regimens that achieve a balance between normal 
growth and development while avoiding hyperandrogenism 
and the risk of adverse events associated with adrenal in-
sufficiency (1). Consistent with recommendations from 
international guidelines, children were reported to be re-
ceiving maintenance GC within the recommended range in 
almost half of clinic visits, with FC doses within recom-
mended dose ranges in 90% of visits. In the current study 
we observed that the likelihood of SDEs was lowest in 
those who were on high doses of GC; future studies should 
also compare the health economic cost of the morbidity as-
sociated with high GC doses against that of adrenal insuffi-
ciency–related adverse events. The dose of 10 to 15 mg/m2/
day used in children with CAH is greater than that gener-
ally recommended for other forms of adrenal insufficiency 
(33), although there are scarce data on doses of GC used 
in children apart from in CAH. Furthermore, the majority 
of patients in our study were very young children and it 
is recognized that children with CAH may have differing 
requirements for GC throughout childhood (19); thus, 
further studies in larger cohorts of children of all ages are 
required.
A greater likelihood of SDE and sick day dosing was also 
observed in boys compared with girls. This is contrary to 
the findings of others where these adverse events were more 
likely in girls (7, 34). While it is clear that newborn boys 
with CAH are more likely to present with a salt-wasting 
crisis when the diagnosis is delayed, it is unclear why boys, 
or for that matter, girls on maintenance therapy would 
have a higher incidence of adrenal insufficiency–related ad-
verse events. The majority of studies in adult populations 
have not revealed a gender difference, although one study 
reported a higher incidence of adverse events in women 
with secondary adrenal insufficiency (35) and another re-
ported a greater incidence in men with concomitant hypo-
gonadism (36). Interestingly, children with a salt-wasting 
phenotype comprised 89% of cases of 21-hydroxylase defi-
ciency in our cohort. This is higher than that previously re-
ported in the literature (2) and may be attributed to several 
factors including the complex mix of cases being entered by 
international clinicians, for example, in countries without 
newborn screening, such as the UK, affected boys may be 
missed or diagnosed with simple virilizing CAH much later 
when signs of androgen excess develop, which may per-
haps lead to delayed entry into disease specific registries. 
The current study also showed that younger (1-4  years) 
and older (15-18  years) age groups had the greatest risk 
of SDE. A higher rate of illness episodes in childhood and 
lower rates of administration of HC injection among very 
young children have been previously reported as reasons 
for this observation (7, 16), with young age also consist-
ently recognized as a risk factor for AC (28, 37). These 
findings may reflect parental uncertainty or inexperience 
with regards to management of illness episodes in children 
(38, 39). A higher rate of SDE in adolescents may be at-
tributed to the period of transition from pediatric to adult 
services, greater patient autonomy, and reduced adherence 
to therapy (9, 40, 41).
It is possible that this study may experience clinician 
and patient retrospective recall bias with subjective re-
porting and a potential for under- or over-reporting of 
SDE and AC. There may have also been a degree of se-
lection bias, as not every patient at a center had been 
included in the I-CAH Registry and among those who 
had been included in this registry, a variable number of 
cases had a sufficient amount of data to be included in 
the study. The lack of a universal definition for “sick day 
episodes” can be considered a limitation. The definition 
of SDE used herein was based on self-reported physician 
diagnosis and clinical judgment of the reporting clinician 
of these events. The current observations highlight the 
limitation of this definition by not showing any value of 
SDEs for predicting AC. A  combination of the variable 
criteria for defining SDEs as well as a variable threshold 
for reporting these adverse events may be an explanation 
for the observed differences. For instance, the higher 
prevalence of SDEs in children from HIC could be attrib-
uted to greater vigilance and reporting of minor illnesses 
among parents and clinicians from higher-income coun-
tries. Interestingly, there was no difference in the number 
of AC events between patients from HIC and LMIC, sug-
gesting an equally effective level of illness management 
and AC prevention. Due to the small number of AC events 
overall, further studies in a larger cohort of patients with 
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required to investigate factors that may influence differ-
ences in the prevalence of ACs as well as SDEs. A better 
definition of SDE may be any episode that requires an 
increase in glucocorticoid replacement above the routine 
replacement dose, as per local sick day rules and to avoid 
an adrenal crisis. However, there is a need for further re-
search to achieve a more effective definition of SDE that 
provides real clinical significance. Furthermore, an online 
system for collecting patient-reported accounts of SDE 
and their management may also prove useful in under-
standing the variation between centers. Lastly, the study 
did not attempt to assess clinical variables such as the 
biochemical adequacy of steroid replacement (42, 43). 
On the other hand, the structured manner of real-world 
data collection within the I-CAH Registry, the size of the 
cohort and its potential to represent global practice with 
the availability of adverse events data for more than half 
of registered patients under the age of 18 years were clear 
strengths. Although, the investigators did not have re-
course to source data, the data that have been collected 
have previously been reported to have a high degree of 
validity, consistency and accuracy (44).
In summary, the real-world data in the I-CAH Registry 
can be used to identify benchmarks for a range of adrenal 
insufficiency–related acute adverse events which seem to 
show clear variation between centers. The current study 
provides the framework that can be used for studying the 
effect of targeted interventions that are aimed at improving 
the care of children with CAH.
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